HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text Full Text (PDF) Supplemental Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jacene, H. A. Articles by Wahl, R. L. Search for Related Content PubMed PubMed Citation Articles by Jacene, H. A. Articles by Wahl, R. L.

Comparison of ⁹⁰Y-Ibritumomab Tiuxetan and ¹³¹I-Tositumomab in Clinical Practice

Russell H. Morgan Department of Radiology and Radiological Science, Division of Nuclear Medicine, Johns Hopkins University, Baltimore, Maryland

View larger version (22K): [in this window] [in a new window]   FIGURE 1.  Platelet counts (A) and ANCs (B) vs. days from radioimmunotherapy are shown for each patient. Mean maximum percentage decline in platelet count was greater in 90Y-ibritumomab tiuxetan group than in 131I-tositumomab group (79% ± 17% vs. 63% ± 28%, P = 0.04). Mean maximum percentage decline in ANC from baseline to nadir was also higher in 90Y-ibritumomab tiuxetan group than in 131I-tositumomab group, but this difference was not statistically significant (75% ± 16% vs. 63% ± 29%, P = 0.09). Time from treatment to ANC nadir was shorter for 90Y-ibritumomab tiuxetan group than for 131I-tositumomab group (36 ± 9 vs. 46 ± 14 d, P = 0.01). Frequency of hematologic support after radioimmunotherapy was similar between 90Y-ibritumomab tiuxetan and 131I-tositumomab groups (P = 1.00, Fisher exact test). Seven patients in 90Y-ibritumomab tiuxetan group and 8 patients in 131I-tositumomab group required blood, platelets, or granulocyte-colony stimulating factor therapy, contributing to sharp upslopes in some curves.

View larger version (12K): [in this window] [in a new window]   FIGURE 2.  Fourteen of 30 patients (47%) had response at 12 wk after radioimmunotherapy. Four had CR (13%) and 10 had PR (33%). Cumulative overall survival was significantly longer for patients who responded to radioimmunotherapy at 12 wk than for those who did not (P 0.05).

View larger version (13K): [in this window] [in a new window]   FIGURE 3.  Overall survival did not significantly differ between patients who received 90Y-ibritumomab tiuxetan and those who received 131I-tositumomab.